ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Internal Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

9,344Medicare Part D Prescriptions Filled, Including Refills

Rank: 151 out of 336

$614K Total Retail Price of All Prescriptions

Rank: 112 out of 336

393 Patients Receiving at Least One Drug in Part D
76%Patients 65 Years and Older
33% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Mississippi
Lower avg

Schedule Two
Controlled Substances

8% of this provider’s 393 patients filled at least one prescription for a schedule two drug, compared to an average of 3%.

Schedule Three
Controlled Substances

15% of this provider’s 393 patients filled at least one prescription for a schedule three drug, compared to an average of 17%.

Risky Drugs to Seniors

3% of this provider’s 6,958 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 2%.

Brand Name Drugs

25% of this provider’s prescriptions were for brand-name drugs, compared to an average of 25%.

Prescription Price

$66 was the average price of a prescription from this provider, compared to $53 among peers.

Prescriptions per Patient

24 is the average number of prescriptions (including refills) per patient, compared to an average of 24.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Mississippi
AMLODIPINE BESYLATE 418 368 1 1
LEVOTHYROXINE SODIUM 309 279 2 7
HYDROCODONE-ACETAMINOPHEN 284 162 S3 3 2
SIMVASTATIN 264 212 4 5
ZOLPIDEM TARTRATE 249 182 5 18
OMEPRAZOLE 193 155 6 3
MELOXICAM 184 171 7 19
ATORVASTATIN CALCIUM 174 118 8 14
ENALAPRIL MALEATE 174 134 8 60
METOPROLOL SUCCINATE 156 117 10 15
FUROSEMIDE 155 103 11 4
METFORMIN HCL 154 121 12 8
PREDNISONE 153 119 13 48
PRAVASTATIN SODIUM 152 128 14 10
FLUTICASONE PROPIONATE 145 98 15 49
PANTOPRAZOLE SODIUM 131 98 16 40
CITALOPRAM HBR 131 90 16 21
GABAPENTIN 126 81 18 11
GLIMEPIRIDE 122 102 19 29
HYDROCHLOROTHIAZIDE 120 88 20 12
DOXYCYCLINE HYCLATE 119 89 21 92
CRESTOR 116 106 22 25
DOXAZOSIN MESYLATE 109 93 23 86
CYMBALTA 103 83 24 52
WARFARIN SODIUM 99 77 25 17
NEXIUM 98 74 26 24
POTASSIUM CHLORIDE 93 60 27 9
LISINOPRIL 92 71 28 6
LOVASTATIN 88 84 29 34
LOSARTAN POTASSIUM 86 68 30 22
DIOVAN 80 66 31 31
CLOPIDOGREL 80 69 31 28
ALLOPURINOL 75 55 33 30
SPIRIVA 70 58 34 88
METOPROLOL TARTRATE 70 53 34 16
FENTANYL 62 35 S2 36 120
POLYETHYLENE GLYCOL 3350 62 53 36 68
ATENOLOL 60 51 38 26
CEFDINIR 60 45 38 216
LIPITOR 58 35 40 62
ALPRAZOLAM 55 0 41 372
ADVAIR DISKUS 54 39 42 82
AMITRIPTYLINE HCL 54 44 R 42 57
PLAVIX 53 46 44 37
NAMENDA 52 52 45 39
CARISOPRODOL 51 13 R 46 63
TRAZODONE HCL 51 36 46 46
ZETIA 51 38 46 74
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on July 10, 2014.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.